Extreme dark cytotoxicity of nile blue A in normal human fibroblasts

Photochemistry and Photobiology

Volumn 74, Issue 5, 2001, Pages 707-711

  Tong, Zhimin ^a,b   Singh, Gurmit ^a,b   Rainbow, Andrew J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NILE BLUE A; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL COUNT; CELL TYPE; COLONY FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG UPTAKE; FAMILIAL CANCER; FIBROBLAST; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGHT; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; TUMOR CELL LINE;

ANIMALS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; DARKNESS; FIBROBLASTS; FLUORESCENT DYES; HUMANS; KINETICS; MICE; OXAZINES;

EID: 0035526518     PISSN: 00318655     EISSN: None     Source Type: Journal    
DOI: 10.1562/0031-8655(2001)074<0707:EDCONB>2.0.CO;2     Document Type: Article

References (35)

1. Dougherty, T. J., C. J. Gomer, B. W. Henderson, G. Jori, D. Kessel, M. Korbelik, J. Moan and Q. Peng (1998) Photodynamic therapy. J. Natl. Cancer Inst. 90, 889-905.
2. Gomer, C. J., N. Rucker, A. Ferrario and S. Wong (1989) Properties and applications of photodynamic therapy. Radiat. Res. 120, 1-18.
3. Lewis, M. R., N. A. Sloviter and P. P. Goland (1946) In vivo staining and retardation of growth of sarcomata in mice. Anat. Rec. 95, 89-96.
4. Lewis, M. R., P. P. Goland and H. A. Sloviter (1949) The action of oxazine dyes in mice. Cancer Res. 9, 736-740.
5. Riley, J. F. (1948) Retardation of growth of a transplantable carcinoma in mice fed basic metachromatic dyes. Cancer Res. 8, 411-418.
6. Bates, J. I. and J. Kershman (1949) Selective staining of experimental brain tumors during life. J. Neuropathol. Exp. Neurol. 8, 411-418.
7. Fowler, G. J., B. C. Rees and R. Devonshire (1990) The photokilling of bladder carcinoma cells in vitro by phenothiazine dyes. Photochem. Photobiol. 52, 489-494.
8. Cincotta, L., J. W. Foley and A. H. Cincotta (1987) Novel red absorbing benzo[a]phenoxazinium and benzo[a]phenothiazinum photosensitizers: in vitro evaluation. Photochem. Photobiol. 46, 751-758.
9. Lin, C. W., J. R. Shulok, Y. K. Wong, C. F. Schanbacher, L. Cincotta and J. W. Foley (1991) Photosensitization, uptake, and retention of phenoxazine Nile blue derivatives in human bladder carcinoma cells. Cancer Res. 51, 1109-1116.
10. Morgan, J., W. R. Potter and A. R. Oseroff (2000) Comparison of photodynamic targets in a carcinoma cell line and its mitochondrial DNA-deficient derivative. Photochem. Photobiol. 71, 747-757.
11. Cincotta, L., J. W. Foley and A. H. Cincotta (1993) Phototoxicity, redox behavior, and pharmacokinetics of benzophenoxazine analogues in EMT-6 murine sarcoma cells. Cancer Res. 53, 2571-2580.
12. Cincotta, L., J. W. Foley, T. MacEachern, E. Lampros and A. H. Cincotta (1994) Novel effects of a benzophenothiazine on two different murine sarcomas. Cancer Res. 54, 1249-1258.
13. Frimberger, A. E., A. S. Moore, L. Cincotta, S. M. Cotter and J. W. Foley (1998) Photodynamic therapy of naturally occurring tumors in animals using novel benzophenothiazine photosensitizer. Clin. Cancer Res. 4, 2201-2218.
14. Yin, Y., M. A. Tainsky, F. Z. Bischoff, L. C. Strong and G. M. Wahl (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70, 937-948.
15. Rodrigues, N. R., A. Rowan, M. E. F. Smith, I. B. Kerr, W. F. Dodmer, J. V. Gannon and D. P. Lane (1990) p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 87, 7555-7559.
16. Thompson-Hehir, J., M. P. Davies, J. A. Green, N. Halliwell, K. A. Joyce, J. Salisbury, D. R. Sibson, I. Vergote and C. Walker (2000) Novel polymerase chain reaction approach for full-coding p53 mutation detection in microdissected archival tumors. Diagn. Mol. Pathol. 9, 110-119.
17. Miyake, H., I. Hara, K. Gohji, K. Yamanaka, S. Arakawa and S. Kamidono (1998) Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53-gene transfer. Anticancer Res. 18, 3087-3092.
18. Davidoff, A. M., J. C. Pence, N. A. Shorter, J. D. Iglehart and J. R. Marks (1992) Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene 7, 127-133.
19. Tong, Z., G. Singh and A. J. Rainbow (2000) The role of the p53 tumor suppressor in the response of human cells to Photofrin-mediated photodynamic therapy. Photochem. Photobiol. 71, 201-210.
20. Levine, A. J. (1997) p53, The cellular gatekeeper for growth and division. Cell 88, 323-331.
21. Zunino, F., P. Perego, S. Pilotti, G. Pratesi, R. Supino and F. Arcamone (1997) Role of the apoptotic response in cellular resistance to cytotoxic agent. Pharmacol. Ther. 76, 177-185.
22. Meilmrath, A. J., P. A. Vasey, G. M. Ross and R. Brown (1994) Cell cycle arrest and radiosensitivity of human tumor cell line: dependence on wild-type p53 for radiosensitivity. Cancer Res. 54, 3718-3722.
23. Gallado, D., K. E. Drazan and W. H. Mcbride (1996) Adenovirus-based transfer of wild-type p53 increase ovrian tumors radiosensitivity. Cancer Res. 56, 4891-4893.
24. Rusch, V., D. Klimstra, E. Venkatrman, J. Oliver, N. Martini, R. Gralla, M. Kris and E. Dmitrovsky (1995) Aberrant p53 expression predicts clinic resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 55, 5038-5042.
25. Yamamoto, M., Y. Meahara, S. Oda, Y. Ichiyoshi, T. Kusumoto and K. Sugimachi (1999) The p53 tumor suppressor gene in anticancer agent-induced apoptosis and chemosensitivity of human gastrointestinal cancer cell lines. Cancer Chemother. Pharmacol. 43, 43-49.
26. Kanamori, Y., J. Kigawa, Y. Minagawa, T. Irie, T. Oishi, M. Shimada, M. Takahashi, T. Nakamura, K. Sato and N. Terakawa (1998) A newly developed adenovirus-mediated transfer of a wild-type p53 gene increase sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells. Eur. J. Cancer 34, 1802-1806.
27. Ueda, K., C. Cardarelli, M. M. Gottesman and J. McIntyre (1987) Expression of a full length cDNA for human MDR1 gene confers resistance to colchicine, doxorubicin and vinblastine. Proc. Natl. Acad. Sci. USA 84, 3004-3008.
28. Chin, K. V., K. Ueda, I. Pastan and M. M. Gottesman (1992) Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255, 459-462.
29. Zastawny, R. L., R. Salvino, J. Chen, S. Benchimol and V. Ling (1993) The core promoter region of the p-glycoprotein gene in sufficient to confer differential responsiveness to wild-type p53 and mutant p53. Oncogene 8, 1529-1535.
30. Denstman, S. C., L. E. Dillehay and J. R. Williams (1987) Enhanced susceptibility to PHD sensitized phototoxicity and correlated resistance to trypsin detachment in SV40 transformed IMR-90 cells. Photochem. Photobiol. 43, 145-147.
31. Fisher, A. M. R., K. Denenberg, D. Banerjee, J. R. Bertino, P. Danenberg and C. J. Gomer (1997) Increased photosensitivity in HL60 cells expressing wild p53. Photochem. Photobiol. 66, 265-270.
32. Fisher, A. M. R., A. Ferrario, N. Ruker, S. Zhang and C. J. Gomer (1999) Photodynamic therapy sensitivity is not altered in human tumor cells after abrogation of p53 function. Cancer Res. 59, 331-335.
33. Chen, X., Z. Wang and L. Zhang (1996) Induction of apoptosis by expression of retroviral mediated wild type p53 gene in a laryngocarcinoma cell line. Chung-Hua Erh Pi Yen Hou Ko Tsa Chih 31, 171-174.
34. Cooper, M. J., J. J. Haluschak, D. Johnson, S. Schwartz, L. J. Morrison, G. Lippa, G. Hatzivassiliou and J. Tan (1994) p53 mutations in bladder carcinoma cell lines. Oncol. Res. 6, 569-579.
35. Kutteh, W. H., D. S. Miller and J. M. Mathis (1996) Immunological characterization of tumor markers in human ovarian cancer cell lines. J. Soc. Gynecol. Investig. 3, 216-222.